Skip to content Skip to sidebar Skip to footer
Phase 3 ASX biotech
This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn
Recce Pharmaceuticals (ASX:RCE,  FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is expecting to complete its Phase 3 trials during FY26 (the 12 months starting on July 1, 2025), and success here would lead to unlocking of market opportunities worth a cumulative US$9.1bn. Specifically, the global DFI…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here